Meet Lily Schwartz, the new executive and artistic director at the Presidio Theatre in San Francisco.

Originally Published: May 16, 2025 at 8:00 AM PDT

SANTA CLARA, Calif. — According to San Francisco 49ers owner Jed York, interested parties have approached his family “probably on a weekly basis” to attempt to buy a piece of the 97% of the team the Yorks own.

This week, it seems, three of the parties who approached the York family came with the right offer. The 49ers are working to complete the sale of more than 6% of the team to three Bay Area families, according to a league source.

Sportico, which first reported the pending sale Thursday, said the sales will be done at a franchise valuation of more than $8.5 billion. If the deal is completed at that number, the valuation will be the largest ever for a sports franchise in a transaction.

The Khosla, Deeter and Griffith families are the prospective buyers, with the Khoslas purchasing 3.1%, the Deeters obtaining 2.1% and the Griffiths acquiring 1%, The Athletic reported Thursday afternoon.

The NFL is expected to formally approve the transactions at the spring owners’ meetings in Minneapolis next week. The 49ers declined to comment on the proposed sales Thursday./p>

br/>The Niners have been receiving offers for the past few months, and York said in March at the annual league meeting that his family had been considering a sale of up to 10% of its ownership stake. At the time, he called it a “family asset allocation decision” based on the wants and needs of various family members.

“It’s just one of those things where if there’s an opportunity that makes sense, we would always explore that, but I’m not sure what we’re going to end up doing,” York said then. “And if we do, we would try to find the right people who would help bolster everything that we’re doing in and around the team, on the field, off the field, and just make sure that we had good partners that are with us.”

All three of the reported buyers have venture capital backgrounds. Vinod Khosla is co-founder of Sun Microsystems and the founder of Khosla Ventures in Menlo Park, California. Byron Deeter is a partner at Bessemer Venture Partners in Redwood City and San Francisco, and William Griffith is a partner at Iconiq Capital in San Francisco.

In other franchise-related news, theLos Angeles Chargersare requesting approval to sell an 8% stake in the team to a private investment firm, The Los Angeles Times reported, citing a person with knowledge of the approval request sent in a memo to NFL owners.

The newspaper said Chargers owner Dean Spanos and siblings Michael Spanos and Alexis Spanos Ruhl will attempt to sell the stake to private investment firm Arctos at next week’s meetings.br/]

On a quiet plot of land in rural New Mexico, Jeff Deming feels like he’s really living, once again.

“Mentally, it’s day and night,” he said.

He’s able to do the things that make him happy, like woodworking, despite living with Parkinson’s Disease.

“Physically, I feel better than I did 2-3 years ago,” he said.

Deming credits the treatment he received during a first-of-its-kind clinical study he participated in at the University of California, San Francisco: Psilocybin therapy for people with Parkinson’s Disease.

“This is very cliché, but it truly gave me my life back,” he said.

Psilocybin is a naturally occurring psychedelic compound found in ‘magic mushrooms.’ When administered in controlled, clinical research settings, it has shown promise in treating depression and anxiety, both of which are mood symptoms associated with Parkinson’s that are linked to a faster physical decline.

“The neurodegeneration that is happening isn’t just impacting motor circuitry – it’s impacting a lot of brain circuitry. That creates this huge burden of symptoms that we often overlook and don’t talk about enough, maybe,” said Dr. Ellen Bradley, of UCSF. “We were really surprised by how well this trial went.”

Bradley and a team of researchers at UCSF are trying to figure out how Psilocybin may help treat mood dysfunction and more in those living with the neurodegenerative disease.

“This is a first step, and now we’ve opened the door to being able to really investigate the effects of Psilocybin for people with Parkinson’s,” she said.

12 patients participated in this first-round study, which involved a first and second course of Psilocybin treatment.

“We had folks do a lower dose of Psilocybin – a 10 mg dose initially – and monitored them for a couple of weeks to see how that went,” Bradley said. “If it did go well, if we didn’t have safety concerns, then they were eligible for the full therapeutic dose of 25 mg.”

All 12 patients were able to complete both courses of treatment without reporting any serious side effects, according to Bradley.

“We want to find out not just does Psilocybin therapy work, but if it does, how does it work? That mechanistic piece is so important,” she said. “Can it change the brain’s ability to adapt to its environment and to rewire itself?”

While there were no serious adverse effects reported, every patient didn’t have the same life-changing experience as Deming says he experienced. Though many did report their motor and cognitive functions improved afterwards, per Bradley.

“We don’t have a reason to believe that this is a treatment that is going to be a good fit for every patient. That is never really our expectation in medicine. But our goal is to figure out when is it the right treatment and how much for which patient,” Bradley said.

Bradley says her team is scaling up their work and are in the process of recruiting for a larger study, due to the success with the initial research.

“That was really exciting just to see that promising safety profile in this initial pilot. That kind of gives us a green light to go forward with more in-depth research,” she said. “We really desperately need new treatments for Parkinson’s. It’s a very quickly growing disease that’s becoming more and more prevalent in our population, so, we really feel like we have to be investigating every possible route that could mean new treatments for patients.”

Two years removed from his controlled Psilocybin dosing, Deming says he feels better now than he did when he received his initial diagnosis four years ago.

“Something about this experience just freed everything back up so I could think again, I could dream again,” he said.

He’d like to see more research into psychedelic therapies for a range of conditions, with the hopes that more people will be able to reclaim the reins of life, as he has.

“There’s been such a stigma against the research with it,” he said. “It is definitely worth looking more closely at.”